Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients

Journal of Clinical Medicine
Roberto RiaAngelo Vacca

Abstract

The interaction between the bone marrow microenvironment and plasma cells plays an essential role in multiple myeloma progression and drug resistance. The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway in vascular endothelial cells activates and promotes angiogenesis. Moreover, VEGF activates and promotes vasculogenesis and vasculogenic mimicry when it interacts with VEGF receptors expressed in precursor cells and inflammatory cells, respectively. In myeloma bone marrow, VEGF and VEGF receptor expression are upregulated and hyperactive in the stromal and tumor cells. It has been demonstrated that several antiangiogenic agents can effectively target VEGF-related pathways in the preclinical phase. However, they are not successful in treating multiple myeloma, probably due to the vicarious action of other cytokines and signaling pathways. Thus, the simultaneous blocking of multiple cytokine pathways, including the VEGF/VEGFR pathway, may represent a valid strategy to treat multiple myeloma. This review aims to summarize recent advances in understanding the role of the VEGF/VEGFR pathway in multiple myeloma, and mainly focuses on the transcription pathway and on strategies that target this pathway.

References

Dec 10, 1991·Biochimica Et Biophysica Acta·P Angel, M Karin
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Jul 1, 1994·British Journal of Haematology·A VaccaF Dammacco
Jan 1, 1995·Annual Review of Cell and Developmental Biology·W Risau, I Flamme
Jun 20, 1998·The Journal of Cell Biology·M ScatenaC M Giachelli
May 26, 1998·Biochemical and Biophysical Research Communications·T OikawaK Tanaka
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Jan 8, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·H C DrexlerM A Konerding
May 9, 2000·Biochemical Pharmacology·T D StephensB J Fillmore
Dec 6, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N G KastrinakisC Kittas
Feb 13, 2001·Mechanisms of Development·D RibattiF Dammacco
May 15, 2001·American Journal of Physiology. Cell Physiology·Y DorE Keshet
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosN Anagnostopoulos
Dec 12, 2001·Seminars in Oncology·A VaccaF Dammacco
Jan 24, 2002·Therapeutic Drug Monitoring·Douglas K PriceWilliam D Figg
Feb 16, 2002·Journal of Hematotherapy & Stem Cell Research·Roberto Stasi, Sergio Amadori
Sep 21, 2002·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Jason M HansenCraig Harris
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarThomas E Witzig
Nov 5, 2002·Nature Reviews. Cancer·Shahin RafiiBeate Heissig
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Jul 12, 2003·Blood·Angelo VaccaFranco Dammacco
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Choon-Kee LeeGuido Tricot
Nov 7, 2003·The Journal of Clinical Endocrinology and Metabolism·Vassiliki PoulakiNicholas Mitsiades
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K ZervasUNKNOWN Greek Myeloma Study Group
Mar 30, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Meletios A DimopoulosAthanasios Anagnostopoulos
Apr 2, 2004·The Journal of Clinical Investigation·Claus CursiefenJ Wayne Streilein
Jun 3, 2004·Lancet·Michael E FranksWilliam D Figg
Sep 17, 2004·Pharmacology & Therapeutics·Aaron N Hata, Richard M Breyer

❮ Previous
Next ❯

Citations

Oct 31, 2020·Cancers·Panagiotis NtellasGeorge Pentheroudakis
Jun 25, 2021·Frontiers in Genetics·Syed Hassan MehdiDonghoon Yoon

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
xenograft
transfection

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.